First Page | Document Content | |
---|---|---|
![]() Date: 2014-03-05 04:20:37Health Genentech Macular degeneration Ranibizumab Novartis Hoffmann-La Roche Off-label use Presumed ocular histoplasmosis syndrome Medicine Pharmacology Bevacizumab | Add to Reading List |
![]() | A Avastin versus Lucentis: Why It Matters lthough Lucentis is a remarkably safe and effective treatment for exudative macular degeneration, it could cost our health care system over $9 billion, whichDocID: 12Y6g - View Document |
![]() | Supplement to australian pharma JUNE 2013DocID: 10GGY - View Document |
![]() | MD Research News Issue 200 Tuesday 30 September, 2014 This free weekly bulletin lists the latest published research articles on macular degeneration (MD) and someDocID: 10cRM - View Document |
![]() | Microsoft Word - Wet AMD_HS Panel_May 2010 _eng_ FINAL.docDocID: Zk2W - View Document |
![]() | Supplement to australian pharma JUNE 2013DocID: Ycn7 - View Document |